The company is working on a novel platform that can accelerate discovery, development, scaling, and delivery of RNA products in a more cost-efficient way.

As well as advanced therapies and vaccines, the technology has potential outside of the biopharma sector, with applications in crop sciences.

GreenLight has a pipeline of RNA products across the human, animal, and plant health sectors.

The company hopes that going public via a SPAC deal, which can be a faster and more low-cost approach, enabling a company to retain control of the process, will help it to accelerate development and commercialization efforts.